Figures as filed · retrieved from SEC EDGAR 2026-10-11
| Company | Fiscal year ended | Revenue | Net income | R&D expense | Source filing |
|---|---|---|---|---|---|
| UnitedHealth Group Incorporated (UNH) | 2025-12-31 | $447.57B | $12.06B | n/d | 10-K filed 2026-03-02 |
| McKESSON CORPORATION (MCK) | 2026-03-31 | $403.43B | $4.76B | n/d | 10-K filed 2026-05-08 |
| CVS HEALTH CORPORATION (CVS) | 2025-12-31 | $402.07B | $1.77B | n/d | 10-K filed 2026-02-10 |
| The Cigna Group (CI) | 2025-12-31 | $274.90B | $5.96B | n/d | 10-K filed 2026-02-26 |
| ELEVANCE HEALTH, INC. (ELV) | 2025-12-31 | $199.13B | $5.66B | n/d | 10-K filed 2026-02-06 |
| HUMANA INC (HUM) | 2025-12-31 | $129.66B | $1.19B | n/d | 10-K filed 2026-02-19 |
n/d = not separately disclosed in that company's filing. Net income and R&D are matched to the same fiscal year as the revenue figure in each row — figures from different fiscal years are never mixed within a row.
Chart, CSV download and embed code
These three tools are in the Free Plan: sign up once to chart the latest-fiscal-year revenue of all 6 companies in this table, download it as a CSV file, or copy its embed code. The table above and everything below it stay open to everyone.
No card, no recurring fee.
What the filings show · Healthcare
Together, the 6 companies in this table reported $1.86T of revenue in their latest fiscal years. UnitedHealth Group Incorporated is the largest at $447.57B, or 24.1% of the table's combined revenue, and HUMANA INC the smallest at $129.66B.
Net margin (net income as a share of revenue) runs from 2.8% at ELEVANCE HEALTH, INC. down to 0.4% at CVS HEALTH CORPORATION. All 6 reported a profit for the year.
These are arithmetic on the reported figures above, nothing more: fiscal years can end on different dates, and a margin or a share says nothing about where a company is heading.
What this table covers · Healthcare
Companies
6
Fiscal years end
2025-12-31 → 2026-03-31
Disclose R&D separately
0 of 6
XBRL revenue tags used
2
Payers and distributors dominate U.S.-listed healthcare by revenue, and neither files research and development as a separate line — their spend is medical costs and distribution, not laboratory research. Expect the R&D column to be empty across this table; that is the sector reporting accurately, not a gap in the data. Revenue scale here is also the largest in the catalogue, which makes percentage comparisons against smaller sectors misleading unless normalised.
The fiscal years in this table end up to 3 months apart, so two rows can describe different twelve-month periods. Each row states its own fiscal-year end for exactly this reason. No company here reports research and development as a separate line, so that column is empty throughout — that is these filings reporting accurately, not missing data. Figures were retrieved from EDGAR on 2026-10-11.
Where every number comes from
Each row comes from that company's latest annual report (Form 10-K) on SEC EDGAR, and the “Source filing” column links the exact submission, so any cell can be checked in one click.
Company selection is a size-and-coverage editorial choice among U.S.-listed 10-K filers in the sector, not a ranking, rating, or recommendation of any company. How every table is built and refreshed is set out once, on the verified data tables methodology.
Primary source
U.S. Securities and Exchange Commission
EDGAR XBRL companyfacts APIThe machine-readable form of the figures each company filed. Per-row filing links above go straight to the submission on sec.gov.
Go deeper on this sector
These are the reported baselines — the questions that decide strategy (share shifts, pricing models, segment growth, what the filings say beneath the totals) are what our research briefs answer. Start with the Healthcare research practice, or size the opportunity yourself with the market-size calculator.
This page does the arithmetic. We check the numbers you put into it.
A table gives you the reported numbers. A verified brief tells you what they mean for your decision — with sources cited and key claims checked. A $29 Verified Snapshot answers one business question in a short, fully cited brief — and its key claims are checked against the sources cited for them before it ships, not just whether the links work.
Get a $29 Verified SnapshotNo recurring fee, nothing to cancel. A brief that does not pass our verification gate is never auto-delivered.
More verified tables
These calculators are provided for general business analysis and are independent informational research — not investment, financial, legal, or tax advice. The arithmetic is standard and openly documented on this page; the assumptions you enter are yours, and the conclusions drawn from them are too.